Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06810375 · ClinicalTrials.gov registry record · Phase 3

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

A Phase 3 study of Lung Cancers, sponsored by George Washington University.

Recruiting
Registry status
Phase 3
Development phase
120
Enrollment target
1
Study location

NCT06810375 is a Phase 3 study of Lung Cancers that is actively recruiting participants, run by George Washington University. The registered enrollment target is 120 participants, below the 158-participant average among 5 other Lung Cancers trials with a reported enrollment target (24% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06810375, a Phase 3 study of Lung Cancers, is actively recruiting participants, sponsored by George Washington University.

RECRUITING
Registry status
Phase 3
Development phase
120 participants
Enrollment target
1
Study location

Study Summary

This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Conditions Studied

Interventions

  • DRUG Erector Spinae (ESP) Block with Bupivacaine (Marcaine®)
  • DRUG Intercostal nerve block

Study Locations (1)

District of Columbia

  • The George Washington University Hospital - Washington D.C.

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2025-03-01
Est. Completion 2029-02-28
Phase Phase 3

Sponsor

George Washington University

133 total trials

What the Registry Record Tells You About NCT06810375

The ClinicalTrials.gov registry entry for NCT06810375 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 158-participant average among 5 other Lung Cancers trials with a reported enrollment target (24% lower). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancers appearing as the primary indexed condition, and to 2 interventions - of which Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) is the first listed.

NCT06810375 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06810375 about?

NCT06810375 is a clinical study titled "Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery". This clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

What is the current status of trial NCT06810375?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2025-03-01. Estimated completion is 2029-02-28.

What conditions does trial NCT06810375 study?

This clinical trial studies the following conditions: Lung Cancers.

What interventions are being tested in trial NCT06810375?

The interventions under investigation include: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) (DRUG), Intercostal nerve block (DRUG).

Who is sponsoring clinical trial NCT06810375?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06810375 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.